Artivion | CRY - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
Abbott USD 3.27B 138M 2026-03
Accuray USD 124.78M 2.54M 2025-12
AngioDynamics USD 36.57M 3.79M 2025-09
Artivion USD 55.75M 4.54M 2025-12
AtriCure USD 84.55M 6.21M 2026-03
Baxter International USD 728M 33M 2026-03
Becton, Dickinson and Co. USD 1.21B 180M 2026-03
Boston Scientific USD 1.78B 53M 2026-03
Edwards Lifesciences USD 522.2M 80.7M 2026-03
Inogen USD 43.77M 510K 2024-06
Integra LifeSciences USD 178.24M 21.79M 2026-03
J&J USD 6.03B 719M 2026-03
Mesa Laboratories USD 27.31M 380K 2024-09
Orthofix International USD 130.35M 11.31M 2025-12
Pfizer USD 2.92B 1.16B 2026-03
ResMed USD 279.8M 1.4M 2026-03
Stryker USD 2.15B 17M 2026-03
Surmodics USD 11.4M 3.18M 2025-06
Tandem Diabetes Care USD 99.86M 5.34M 2025-12
Teleflex USD 226.01M 3.64M 2026-03
Terumo JPY 114.81B 9.55B 2026-03
Trinity Biotech USD 6.19M 2.18M 2025-09